Tachycardia, Ventricular Clinical Trial
— SMSOfficial title:
Substrate Modification Study in Patients Getting an ICD
Verified date | September 2017 |
Source | Medtronic Bakken Research Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present standard of care for the management of unstable ventricular tachycardia (VT) in
the setting of chronic coronary artery disease is the placement of an implantable
cardioverter defibrillator (ICD) after the initial episode, and radiofrequency ablation
and/or antiarrhythmic medication in the event of recurrences causing frequent ICD
interventions.
The primary purpose of this randomized study is the assessment of recurrences of unstable VT
in patients who undergo ICD implantation plus substrate ablation after the initial episode
compared to patients who only undergo ICD implantation. Thus the primary purpose is an
improvement in the quality of life. A decrease in mortality is not a primary purpose of this
study.
Status | Completed |
Enrollment | 116 |
Est. completion date | August 2011 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Coronary artery disease documented by coronary angiography. For the purpose of this study, coronary artery disease will be defined as the presence of a 50% or more diameter stenosis of the left main or of a 75% or more diameter stenosis of the left anterior descending, circumflex or right coronary arteries, or the history of a surgical or percutaneous revascularization procedure. - Left ventricular ejection fraction < 40% as estimated by echocardiography or contrast ventriculography within the previous 30 days. - Clinical unstable VT without reversible factors (acute ischemia or antiarrhythmic medications as defined below). Unstable VT can have one of the following clinical presentations: - Hypotensive VT without major neurologic dysfunction; - Syncope; or - Cardiac arrest. Exclusion Criteria: - Age < 18 years or > 80 years - Protruding left ventricular (LV) thrombus on pre-ablation echocardiogram - Acute myocardial infarction within the preceding 2 months - Class IV New York Heart Association (NYHA) heart failure - Valvular heart disease or mechanical heart valve precluding access to the left ventricle - Unstable angina - Cardiac surgery within the past 2 months - Serum creatinine > 220 mmol/L (2.5 mg/dL) - Thrombocytopenia or coagulopathy - Contraindication to heparin - Pregnancy - Acute illness or active systemic infection - Other disease process likely to limit survival to less than 12 months - Significant medical problem that, in the opinion of the principal investigator, would preclude enrollment into the study - Participation in another investigational study - Unwillingness to participate or lack of availability for follow-up |
Country | Name | City | State |
---|---|---|---|
Denmark | Skejby Skygehus | Aarhus | |
Germany | Herz- und Gefäßklinik GmbH | Bad Neustadt / Saale | |
Germany | Berufsgenossenschaftliche Kliniken Bergmannsheil | Bochum | |
Germany | Klinikum der J.W. Goethe Universität | Frankfurt | |
Germany | Allgemeines Krankenhaus St. Georg | Hamburg | |
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Klinikum der Stadt Ludwigshafen am Rhein | Ludwigshafen |
Lead Sponsor | Collaborator |
---|---|
Medtronic Bakken Research Center | Medtronic |
Denmark, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to the first documented recurrence of any sustained VT/ventricular fibrillation (VF) during the follow-up period | 12 Months | ||
Secondary | All appropriate ICD therapies (number of shocks, number of antitachycardia pacing therapies) | 12 Months | ||
Secondary | Quality of life | 12 Months | ||
Secondary | Number of hospital readmissions due to a cardiac indication | 12 Months | ||
Secondary | Severe clinical events | 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01546207 -
Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia
|
N/A | |
Completed |
NCT04070300 -
Physical Activity and Ventricular Arrhythmias
|
N/A | |
Completed |
NCT04075253 -
Acute Effect of One Single Bout of High Intensity Exercise on the Tendency for Ventricular Arrhythmia
|
N/A | |
Completed |
NCT00000531 -
Antiarrhythmics Versus Implantable Defibrillators (AVID)
|
Phase 3 | |
Completed |
NCT00000480 -
Multicenter Unsustained Tachycardia Trial (MUSTT)
|
Phase 3 | |
Completed |
NCT05086510 -
Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
|
N/A | |
Completed |
NCT01940081 -
The Leiden Nonischemic Cardiomyopathy Study
|
||
Recruiting |
NCT01222156 -
Accuracy and Safety Study of the Magnetecs CGCI System for Intracardiac Mapping
|
Phase 1/Phase 2 | |
Terminated |
NCT00749671 -
Bispectral Index Monitoring During Testing in the Electrophysiology Lab
|
N/A | |
Recruiting |
NCT00385749 -
Right Ventricular Defibrillation Lead Select Site Study
|
N/A | |
Completed |
NCT00382928 -
Automatic External Defibrillation Monitoring in Cardiac Arrest
|
Phase 1 | |
Completed |
NCT00279279 -
PREPARE - Primary Prevention Parameters Evaluation
|
N/A | |
Terminated |
NCT00776087 -
European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)
|
N/A | |
Withdrawn |
NCT00510731 -
The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events
|
N/A | |
Completed |
NCT01572246 -
Effects of Monopolar Electrocautery Use During Surgery on Implanted Cardiac Defibrillators
|
N/A | |
Completed |
NCT00147277 -
ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
|
Phase 4 | |
Completed |
NCT00004559 -
Fatty Acid Antiarrhythmia Trial (FAAT)
|
Phase 3 | |
Completed |
NCT00702117 -
Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias
|
Phase 4 | |
Completed |
NCT00232297 -
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS
|
Phase 2 | |
Active, not recruiting |
NCT01639365 -
SmartTouch Catheter in Ablation of Ventricular Tachycardia
|
N/A |